WP
SYRE icon

Woodline Partners’s Spyre Therapeutics SYRE Stock Holding History

Woodline Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.2M Buy
306,049
+40,157
+15% +$2.93M 0.08% 303
2026
Q1 		$13.4M Hold
265,892
– – 0.05% 440
2025
Q4 		$8.71M Buy
265,892
+134,016
+102% +$3.5M 0.03% 493
2025
Q3 		$2.21M Sell
131,876
-333,276
-72% -$5.43M 0.01% 717
2025
Q2 		$6.96M Buy
465,152
+344
+0.1% +$5.09K 0.04% 503
2025
Q1 		$7.5M Buy
464,808
+112,128
+32% +$2.33M 0.05% 412
2024
Q4 		$8.21M Buy
352,680
+88,424
+33% +$2.59M 0.06% 389
2024
Q3 		$7.77M Buy
264,256
+1,640
+0.6% +$45.7K 0.07% 335
2024
Q2 		$6.17M Buy
262,616
+162,089
+161% +$5.47M 0.06% 317
2024
Q1 		$3.81M Buy
+100,527
New +$2.91M 0.04% 389

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Woodline Partners's SYRE Position: Q2 2026 in Review

Woodline Partners increased its Spyre Therapeutics (SYRE) stake by 15% in Q2 2026, buying an estimated $2.93M and bringing the position to 306,049 shares worth $27.2M. The position accounts for 0.08% of the portfolio, ranked #303.

Woodline Partners first reported a position in SYRE in Q1 2024 and has held it in 10 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Woodline Partners held 306,049 shares of Spyre Therapeutics worth $27.2M as of Q2 2026.
  • Woodline Partners bought 40,157 Spyre Therapeutics shares in Q2 2026, an estimated $2.93M.
  • Spyre Therapeutics made up 0.08% of Woodline Partners's portfolio in Q2 2026, its #303 holding.
  • Woodline Partners first reported a position in Spyre Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.